2022 Chinese IVD Companies Q1 Released —— Autobio, BSBE, Easy Diagnosis, Medicalsystem, Dian Diagnostics, Hybribio, Kingmed

Autobio Diagnostics CO.,Ltd. (603658.SH)

CACLP Booth NO. A4-1309

On April 27, Autobio released its annual report for the first quarter of 2022. In the first quarter, the total operating income was CNY 1.03 billion, a year-on-year increase of 26.2%; the net profit attributable to the parent was CNY 240 million, a year-on-year increase of 40.1%; earnings per share were CNY 0.41 yuan.

Beijing Strong Biotechnologies,Inc. (300406.SZ)

CACLP Booth NO. A4-0101

On April 27, BSBE released its annual report for the first quarter of 2022. In the first quarter, the total operating income was CNY 3.73 billion, a year-on-year decrease of 0.29%; the net profit attributable to the parent was CNY 98.1103 million, a year-on-year decrease of 12.53%; earnings per share were CNY 0.17 yuan.

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)

CACLP Booth NO. A4-1314

On April 27, Easy Diagnosis released its annual report for the first quarter of 2022.In the first quarter, the total operating income was CNY 2.49 billion, a year-on-year increase of 267.4%; the net profit attributable to the parent was CNY 1.39 billion, a year-on-year increase of 307.1%; earnings per share were CNY 13.51.

Medicalsystem Biotechnology Co.,Ltd. (300439.SZ)

CACLP Booth NO. A5-1309

On April 27, Medicalsystem released its annual report for the first quarter of 2022. In the first quarter, the total operating income was CNY 580 million, an increase of 8.7% year-on-year; the net profit attributable to the parent was CNY 69.561 million, a year-on-year decrease of 7.9%, and earnings per share were CNY 0.18.

Dian Diagnostics Group CO.,LTD. (300244.SZ)

CACLP Booth NO. A3-1709

On April 27, Dian Diagnostics released its annual report for the first quarter of 2022. In the first quarter, the total operating income was CNY 4.65 billion, a year-on-year increase of 62.1%; the net profit attributable to the parent was CNY 750 million, a year-on-year increase of 122.6%; earnings per share were CNY1.21.

Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)

CACLP Booth NO. A1-2609

On April 27, Hybribio released its annual report for the first quarter of 2022. In the first quarter, the total operating income was CNY 1.51 billion, a year-on-year increase of 147.9%; the net profit attributable to the parent was CNY 500 million, a year-on-year increase of 190.6%; earnings per share were CNY 1.72.

Guangzhou Kingmed Diagnostics Group Co.,Ltd. (603882.SH)

On April 27, Kingmed released its annual report for the first quarter of 2022. In the first quarter, the total operating income was CNY 4.25 billion, a year-on-year increase of 58.7%; the net profit attributable to the parent was CNY 850 million, a year-on-year increase of 58%; earnings per share were CNY1.83.